ribosomal protein S4X pseudogene 14Genealiases: []
Q-omics provides the consensus-scored RPS4XP14 profile across patient tissues and cancer cell-line models. RPS4XP14 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, RPS4XP14 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, RPS4XP14 RNA expression shows 15,199 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUSC, COAD, and ACC as cancer lineages where RPS4XP14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS4XP14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS4XP14 survival associations across molecular data types. RPS4XP14 RNA expression shows survival associations in the most cancer types (28). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS4XP14 RNA expression–survival associations across cancer types. High RPS4XP14 expression shows unfavorable associations in PAAD, but favorable associations in LUSC, THCA, CESC, CHOL and KIRC. The LUSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify LUSC as the clearest survival context for RPS4XP14 RNA expression.
This table summarizes RPS4XP14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPS4XP14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS4XP14 shows lower tumor expression in UCEC and higher tumor expression in COAD, LIHC, CHOL, KIRC and LUAD. The COAD box plot shows higher RPS4XP14 RNA expression in tumor versus normal tissue (log2 FC = +1.089, t-test p < 0.001).
This table shows molecular features associated with RPS4XP14 in patient tissues and cancer cell lines. In patient samples, RPS4XP14 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
